1. Home
  2. SPPL vs APVO Comparison

SPPL vs APVO Comparison

Compare SPPL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPPL

SIMPPLE LTD.

HOLD

Current Price

$4.60

Market Cap

19.5M

Sector

N/A

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPPL
APVO
Founded
2016
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
21.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SPPL
APVO
Price
$4.60
$1.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1K
1.1M
Earning Date
04-10-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,591,508.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.27
N/A
52 Week Low
$2.18
$1.00
52 Week High
$16.80
$109.80

Technical Indicators

Market Signals
Indicator
SPPL
APVO
Relative Strength Index (RSI) 47.62 37.76
Support Level $4.30 $1.00
Resistance Level $5.36 $1.11
Average True Range (ATR) 0.36 0.09
MACD 0.04 -0.01
Stochastic Oscillator 46.48 17.07

Price Performance

Historical Comparison
SPPL
APVO

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: